Anti-Obesity Drugs

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. Industry Overview

• Current & Future Analysis
• Factors Influencing the Market
• Obesity - A Global Epidemic
• Table 1: Global Overweight Prevalence (2006): Overweight Population (%) of Select Countries (includes corresponding Graph/Chart)
• Table 2: Abdominal Obesity Prevalence (%) by Region and Sex (includes corresponding Graph/Chart)
• Trends and Issues
• Obesity: An Unmet Medical Need
• Rising Demand for Obesity Therapeutics
• Barriers to Development of Effective Drugs
• New Research Aids in Discovery of Novel Drugs
• Growing Problem of Obesity in Asia Particularly China

2. Competition

• Roche Leads the Race
• Table 3: Leading Brands in the Global Anti-obesity Drugs Market (2007): Percentage Share Breakdown of Revenues for Xenical/orlistat, Reductil/Meridia (sibutramine), Alli, Acomplia and Others (includes corresponding Graph/Chart)
• Competition Grows with Pipeline Drugs
• Current Anti-Obesity Drugs in Pipeline: 2008

3. Obesity - An Introduction

• Diagnosis of Obesity
• BMI Calculation and Classification
• Waist Circumference and BMI
• Causes of Obesity
• Unhealthy Eating Habits
• Environmental and Genetic Factors
• Sedentary Lifestyle
• Alcohol Intake
• Childhood Obesity
• Psychological Factors
• Pregnancy
• Hormonal Disorders
• Drugs
• Aging
• Risks Associated with Obesity

4. Obesity Treatment

• Dietary Therapy
• Exercise Therapy
• Behavior Therapy
• Pharmacotherapy
• Weight Loss Surgery
• Invasive Vis-a-vis Non-invasive Procedures
• A Brief Review of Select Invasive Procedures
• Bariatric Surgery
• Laparoscopic Adjustable Gastric Banding
• Vertical Banded Gastroplasty (VBG)
• Roux-en-Y Gastric Bypass Procedure (RYGB)
• Lap-Band Procedure
• Gastric Band Procedure
• Gastric Bypass Procedure
• Doudenal Switch
• Prescription Drugs Vis-a-vis Non-Prescription Drugs
• Table 4: Obesity Treatment Options and Corresponding Success Rate

5. Anti-Obesity Drugs- An Insight

• Introduction
• Mechanism of Action
• Review of Available Drugs
• Phentermine
• Sibutramine
• Orlistat
• Anti-obesity Drugs, Brands and Mechanism of Action
• Table 5: Global Anti-obesity Prescription Drugs Market (2006): Percentage Share Breakdown of Prescriptions by Physician Practices - Primary Care Physicians (PCP), Internal Medicine, Obsterics/Gynecology, Endocrinology/Diabetes, Psychiatry/Neurology, Cardiology and Others (includes corresponding Graph/Chart)
• Review of Select Drugs Awaiting approval / Under Trials

6. Recent Clinical Trials

• Genaera Initiates First Human Trial of Trodusquemine
• Neurogen Completes First Trial of NGD-4715
• Alizyme Secures USFDA Approval for Cetilistat Trials
• GW Pharma to Start Human Trials of New Anti Obesity Drug
• Epix Completes Phase Ib Trial of PRX - 07034
• 7TM Pharma Starts Phase I/II Trial of TM30339
• Arena Starts Phase III Clinical Trials of Lorcaserin
• Drug Induced Serotonin Could Promote Weight Loss
• Takeda Initiates Phase II Clinical Trials of ALT-962
• Glenmark to Commence Phase I Trial of New Anti-Obesity Drug
• Amylin-Leptin Integrated Therapy to Treat Obesity
• Vivus Completes Phase II Trial of Qnexa
• VERNALIS Starts Phase I trial for Obesity
• 7TM Pharma Completes Phase I/ II Clinical Trials of TM30338
• Manhattan Pharmaceuticals Starts Phase I trial of Oleoyl estrone
• Arena Completes Phase2b Trials of APD356
• Metabolic Accomplishes Phase 2b Trials of AOD9604

7. Product Approvals/Launches

• Sanofi-Aventis Receives Swiss Approval for Acomplia
• Zydus Cadila Introduces Slimona
• Torrent Introduces Rimoslim
• Gencor Introduces Slimaluma
• Orexigen Develops Excalia
• Scripps Research Institute Develops Vaccine for Obesity
• Sanofi-Aventis Receives Approval to Market Obesity Drug in EU
• Sanofi-Aventis Rolls Out Acomplia
• Sanofi Secures Approval for Acomplia in the UK
• Novo Nordisk to Develop Anti-obesity Drug
• Sanofi-Aventis Receives Approval to Market Acomplia in Mexico
• Ind-Swift Introduces Sibuslim-10
• Wellnx Launches NV
• Iron-Tek Introduces Appetite Suppressant
• Yamanouchi and Keio University Discover Target Molecule for Developing Anti-obesity Drug

8. Recent Industry Activity

• Pfizer Halts CP-945, 598 Development
• Shionogi to Acquire Sciele Pharma
• Anthill Inks Agreement with Zafgen
• EMEA Suspends Acomplia
• GlaxoSmithKline to Sell Alli as OTC Drug
• Sanofi-Aventis to Market Acomplia in UK
• Orexigen Receives 4th US Patent for Contrave
• BELLUS Health to Acquire Innodia
• Ore Secures License to Develop Romazarit
• GlaxoSmithKline Receives FDA Approval for Orlistat
• Pfizer Receives Approval for Slentrol
• GlaxoSmithKline Secures Licensing Rights of Orlistat
• Pfizer Collaborates with Bristol-Myers Squibb
• Takeda Collaborates with LG Life Sciences
• Takeda to Acquire Paradigm
• Sanofi-Aventis Secures Reimbursement Status for Acomplia
• AstraZeneca Inks Agreement with Palatin Technologies
• Switzerland Includes Acomplia in Reimbursement List
• Allergan Pockets EndoArt
• Sanofi-Aventis Receives Approval for Acomplia in Brazil
• Biocon Inks MoU with Neopharma
• Aurigene Partners with Forest Laboratories
• Pfizer Licenses Obesity Compounds from Bayer Pharmaceuticals
• Merck Terminates Collaboration with Nastech
• Sanofi-Aventis to Receive Rights for Rimonabant
• UMN Pharma Inks Agreement with Crucell and DSM Biologics
• 7TM Pharma Pockets CareX SA
• BioLineRx Inks Licensing Agreement with Yissum
• Aegis Inks Licensing Agreement with Albany Medical College
• Manhattan' s Obesity Drug Approved for Human Trials
• Chugai Halts Development of Anti-Obesity Agent
• HSG Acquires Polymann
• Orchid Pockets Bexel

9. Focus on Select Players

• Abbott Laboratories (US)
• Alizyme Plc (UK)
• Amylin Pharmaceuticals, Inc. (US)
• AstraZeneca Plc (UK)
• F. HOFFMANN-LA ROCHE LTD. (Switzerland)
  • GlaxoSmithKline Plc (UK)
  • Sanofi-Aventis SA (France)
  • SuperGen, Inc. (USA)
  • Takeda Pharmaceutical Company Limited (Japan)
  • VIVUS, Inc. (US)

10. Global Market Perspective

• Table 6: World Recent Past, Current & Future Market Analysis for Anti-Obesity Drugs by Geographic Region - US, Europe and Rest of World Independently Analyzed with Annual Sales Figures in US$ million for Years 2005 through 2015 (includes corresponding Graph/Chart)
• Table 7: World 10-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Market Overview
  • Table 8: Leading Product Segments in the US Weight Loss Market (2008E): Percent Share Breakdown of Revenues for Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods, Artificial Sweeteners, Weight Loss Centers, Medically Supervised Programs, Meal Replacements & Appetite Suppressants, Prescription Drugs, Low Calorie Diet Programs and Others (includes corresponding Graph/Chart)
  • Obesity Catching Them Young
  • New Drugs to Rule the Market
  • 37 States Experience Increase in Adult Obesity Rate
  • Statistical Data
  • Table 9: US Obesity Rate (2007): Prevalence Rate of Leading States
  • Table 10: US Obesity Prevalence Estimates and Forecasts (2006-2020) (includes corresponding Graph/Chart)
  • Table 11: US Overweight Prevalence (1998 & 2002): Breakdown of Adult population by Category - Overweight and Obese
  • Table 12: US Obesity Prevalence (2005-2006): Breakdown of Population (%) by Sex and Age Group (includes corresponding Graph/Chart)
  • Table 13: US Anti-obesity Drugs Market (2006 & 2007): Number of Obese People Treated in Million
  • Reimbursement Scenario
  • Regulatory Environment
  • Insufficient Regulatory and Enforcement Laws
  • Obesity and Related Ailments: Burden on Societal and Economic Cost
  • Competition
  • Table 14: US Anti-obesity Drugs Market (2006 and 2007): Percentage Share Breakdown of Revenues by Brand - Meridia, Xenical and Others (includes corresponding Graph/Chart)
  • Recent Clinical Trials
  • Product Approval/Launches
  • Strategic Corporate Developments
  • Review of Major Players
• B. Market Analytics
  • Table 15: US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2. Europe

• A. Market Analysis
  • Market Overview
  • Lack of Reimbursement: Barrier to Market Growth
  • Statistical Data
  • Table 16: Obesity Prevalence (2007) in Select European Union Countries: Obesity Rates by Gender (includes corresponding Graph/Chart)
  • Table 17: Europe Obesity Prevalence (2007) by Gender and Age Category (in 000s) (includes corresponding Graph/Chart)
  • Overview of Novel Policies Adopted by Select European Countries to Prevent Obesity
• B. Market Analytics
  • Table 18: European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
  • Table 19: European 10-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart)

2a. France

• A. Market Analysis
  • Market Overview
  • Changing Lifestyle Alter Health Profile
  • Product Approval/Launches
  • Strategic Corporate Developments
  • Sanofi-Aventis SA - A Key Player
• B. Market Analytics
  • Table 20: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2b. Germany

• A. Market Analysis
  • Table 21: German Anti-obesity Drugs Market (2005 and 2006): Percentage Share Breakdown of Volume Sales by Leading Brands - Meridia and Xenical and Others
• B. Market Analytics
  • Table 22: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2c. Italy

• Market Analysis
• Table 23: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2d. The United Kingdom

• A. Market Analysis
  • Market Overview
  • Table 24: UK Childhood Prevalence (1995-2005): Percentage of Obese Children Aged 2-15 years (includes corresponding Graph/Chart)
  • Recent Clinical Trials
  • Product Approval/Launches
  • Strategic Corporate Developments
  • Review of Major Players
• B. Market Analytics
  • Table 25: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2e. Rest of Europe

• A. Market Analysis
  • Recent Clinical Trials
  • Product Approval/Launches
  • Strategic Corporate Developments
  • F. HOFFMANN-LA ROCHE LTD. - A Key Player
• B. Market Analytics
  • Table 26: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

3. Rest of World

• A. Market Analysis
  • Brief Review of Select Regions
  • Canada
  • Table 27: Canadian Obesity Prevalence (1979 & 2004): Obesity Rate by Age Group (includes corresponding Graph/Chart)
  • Table 28: Canadian Adult Overweight and Obesity Prevalence (2004): Breakdown of Population (in 000s) by Sex
  • Asia-Pacific
  • Australia
  • Table 29: Prevalence Rate (%) of overweight/obese Students in Australia (includes corresponding Graph/Chart)
  • China
  • India
  • Drugs Under Development by Indian Companies
  • Japan
  • Takeda Pharmaceutical Company Limited - A Key Player
  • Korea
  • Use of Diet Pills Lack Proper Monitoring
  • New Zealand
  • Recent Clinical Trials
  • Product Approval/Launches
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 30: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE